Author Interviews, Geriatrics, Heart Disease, Lipids / 18.07.2019
Older Patients May Benefit from Combination of Simvastatin-Ezetimibe After Acute Coronary Syndrome
MedicalResearch.com Interview with:
Richard G. Bach, MD FACC
Professor of Medicine
Washington University School of Medicine
Director, Cardiac Intensive Care Unit
Director, Hypertrophic Cardiomyopathy Center
Barnes-Jewish Hospital
St. Louis, MO 63110
MedicalResearch.com: What is the background for this study?
Response: Elderly patients represent the largest group of those hospitalized for an acute coronary syndrome, and age is an important marker of increased risk. The risk of death and recurrent cardiovascular events is greatest among the elderly. High intensity lipid lowering by statins has been shown to reduce the incidence of recurrent cardiovascular events after an acute coronary syndrome in general, but there remains limited data on efficacy and safety of that treatment in the elderly, and guidelines do not routinely advocate higher intensity treatment for patients older than 75 years. In practice, older age has been associated with a lower likelihood of being prescribed intensive lipid lowering therapy. IMPROVE-IT evaluated the effect of higher-intensity lipid lowering with ezetimibe combined with simvastatin compared with simvastatin-placebo among patients after ACS, and observed that ezetimibe added to statin therapy incrementally lowered LDL-cholesterol level and improved CV outcomes. IMPROVE-IT enrolled patients with no upper age limit, which gave us the opportunity to examine the effect of age on outcome on the benefit of more intensive lipid lowering with ezetimibe combined with simvastatin vs. simvastatin monotherapy.
(more…)